Expertise in
26
conditions

Hong C. Shen

West Lake Rd 38, 
Hangzhou, CN 
 (7453.5 mi)
Expertise in
26
conditions
West Lake Rd 38, 
Hangzhou, CN 
 (7453.5 mi)
OverviewLocationsClinical Research

Overview

Hong Shen practices in Hangzhou, China. Shen is highly rated in 26 conditions, according to our data. Her top areas of expertise are Parathyroid Cancer, Kerion Celsi, Parathyroid Adenoma, Reconstructive Urology Surgery, and Laryngectomy.

Her clinical research consists of co-authoring 960 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

West Lake Rd 38, Hangzhou, 310009, China
Other Locations
No. 28 Fuxing Rd, Beijing, 100853, China
No. 264, Guangzhou Road, Nanjing, China
Building 5, No. 371, Lishizhen Road, Shanghai, 201203, China
No. 759 Erhuan East Road, Huzhou, 313000, China
197, Rui Jin Er Rd, Shanghai, 200025, China
No. 155 Hanzhong Road, Nanjing, 210029, China
720 Cai Lun Road, Shanghai, 201203, China
Department Of Otorhinolaryngology Head And Neck Surgery, Beijing, China
Number 20, Third Section Of People's South Road, Chengdu, 610000, China
Yihuan Road, Chengdu, 610065, China
No.88 Jiefang Road, Hangzhou, 310009, China
600 Yishan Rd, Shanghai, 200233, China
600 Yishan Road, Shanghai, 200233, China
483 Wushan Road, Guangzhou, 510642, China
720 Cailun Road, Shanghai, 201203, China
23 Youzheng Street, Harbin, 150001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
Enrollment Status: Completed
Publish Date: July 22, 2024
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 3 Less Clinical Trials

960 Total Publications

Gentiopicroside alleviates neuroinflammation in Parkinson's disease by mediating microglial pyroptosis via the NF-κB/NLRP3/GSDMD pathway.
Gentiopicroside alleviates neuroinflammation in Parkinson's disease by mediating microglial pyroptosis via the NF-κB/NLRP3/GSDMD pathway.
Journal: Histology and histopathology
Published: February 04, 2025

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile